The EMA has recommended an immediate suspension and recall of Zinbryta, a multiple sclerosis drug from Biogen Inc. and AbbVie Inc. after the death of three patients.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
Celgene has entered into a multi-year partnership with biotech firm Vividion Therapeutics, in a bid to accelerate its proteomics and chemistry platforms.
The FDA has announced a plan to modernise its approach to evaluating new drugs for Alzheimer’s and other neurologic diseases.
Designed to accelerate pre-clinical genomic research and drug discovery for the benefit of patients, the team behind the global genomic data marketplace has grown by nearly 50% in the past year.
Helix has successfully closed a $200 million financing round, and has revealed that it plans to expand its personal genomics marketplace to accelerate consumer adoption of genomics.
Shares in Celgene, one of biotech’s most successful companies, has dropped 9% following a drug refusal from the Food and Drug Administration.
AstraZeneca has made the decision to push six early-stage experimental drugs into a new $250 million standalone biotech company focused on severe autoimmune diseases.
U.S. drugmaker Gilead Sciences has announced that it will use Sangamo Therapeutics gene-editing technology to develop cancer treatments in a deal worth potentially $3 billion to Sangamo.
AstraZeneca has secured approval for one of its key new lung cancer drugs, cementing the medicine’s potential to become a blockbuster treatment.